ATE367164T1 - Verwendung von 4-thiouridin oder isomaltitol zur behandlung von entzündungen und/oder hämostasis - Google Patents
Verwendung von 4-thiouridin oder isomaltitol zur behandlung von entzündungen und/oder hämostasisInfo
- Publication number
- ATE367164T1 ATE367164T1 AT00937418T AT00937418T ATE367164T1 AT E367164 T1 ATE367164 T1 AT E367164T1 AT 00937418 T AT00937418 T AT 00937418T AT 00937418 T AT00937418 T AT 00937418T AT E367164 T1 ATE367164 T1 AT E367164T1
- Authority
- AT
- Austria
- Prior art keywords
- hemostasis
- isomaltitol
- thiouridine
- treat inflammation
- uridine
- Prior art date
Links
- 230000023597 hemostasis Effects 0.000 title abstract 3
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 title 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 title 1
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 abstract 4
- 208000038016 acute inflammation Diseases 0.000 abstract 2
- 230000006022 acute inflammation Effects 0.000 abstract 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 abstract 2
- 208000037976 chronic inflammation Diseases 0.000 abstract 2
- 230000006020 chronic inflammation Effects 0.000 abstract 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 abstract 2
- 229940045145 uridine Drugs 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9901615A SE521031C2 (sv) | 1999-05-05 | 1999-05-05 | Nya specifika inhibitorer av akut och kronisk inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE367164T1 true ATE367164T1 (de) | 2007-08-15 |
Family
ID=20415466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00937418T ATE367164T1 (de) | 1999-05-05 | 2000-05-02 | Verwendung von 4-thiouridin oder isomaltitol zur behandlung von entzündungen und/oder hämostasis |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20020061863A1 (de) |
| EP (2) | EP1790348A3 (de) |
| JP (1) | JP2002544165A (de) |
| AT (1) | ATE367164T1 (de) |
| AU (1) | AU776520B2 (de) |
| BR (1) | BR0010283A (de) |
| CA (1) | CA2373052A1 (de) |
| DE (1) | DE60035583T2 (de) |
| SE (1) | SE521031C2 (de) |
| WO (1) | WO2000067759A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE529064C2 (sv) * | 2005-01-03 | 2007-04-24 | Selectica Pharmaceuticals Ab | Topiska kompositioner |
| AU2008324033B2 (en) * | 2007-11-05 | 2014-01-09 | Humanitarian Scientific Llc | Sulfonated precursors of thymidine for the treatment of epithelial hyperplasias |
| WO2019112383A1 (ko) * | 2017-12-08 | 2019-06-13 | 윤주석 | 금속 미네랄 디아미네이트 및 이의 제조방법 |
| CN114469981A (zh) * | 2021-12-16 | 2022-05-13 | 中国科学院动物研究所 | 尿苷在促进组织器官再生或治疗和/或预防和/或缓解和/或改善组织器官损伤中的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2217628C2 (de) * | 1972-04-12 | 1974-06-06 | Sueddeutsche Zucker Ag | Verfahren zur Herstellung von alpha-D-Glucopyranosido eckige Klammer auf 1-6 eckige Klammer zu sorbit (Isomaltit) |
| DE2307251C2 (de) * | 1973-02-14 | 1984-03-29 | Süddeutsche Zucker AG, 6800 Mannheim | Arzneimittel zur Behandlung von chronischer Obstipation und Leberschäden |
| HK1005740A1 (en) | 1987-10-28 | 1999-01-22 | Wellstat Therapeutics Corporation | Acylated uridine and cytidine and uses thereof |
| US5691320A (en) * | 1987-10-28 | 1997-11-25 | Pro-Neuron, Inc. | Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis |
| US5470838A (en) * | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
| US6329350B1 (en) * | 1987-10-28 | 2001-12-11 | Pro-Neuron, Inc. | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| US5607925A (en) * | 1988-11-15 | 1997-03-04 | Merrell Pharmaceuticals Inc. | Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides |
| MX9203459A (es) * | 1988-11-15 | 1992-08-01 | Merrell Pharma Inc | Nuevos derivados de 2'-halometilideno, 2'-etenilideno y 2'-etinilcitidina, uridina y guanosina. |
| JP2529605B2 (ja) | 1989-10-23 | 1996-08-28 | 株式会社大塚製薬工場 | 免疫賦活剤 |
| IT1241984B (it) * | 1990-06-13 | 1994-02-02 | Polifarma Spa | Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete |
| DK0600930T3 (da) * | 1991-08-02 | 2002-12-02 | Denise L Faustman | Diagnose og behandling af autoimmune sygdomme |
| US5229415A (en) | 1992-03-24 | 1993-07-20 | Merck & Co., Inc. | Alkylthio alkyl avermectins are active antiparasitic agents |
| US5646182A (en) * | 1992-06-15 | 1997-07-08 | Burzynski; Stanislaw R. | Methods for treating autoimmune diseases |
| CA2588495C (en) * | 1992-12-08 | 2009-11-17 | Wellstat Therapeutics Corporation | The utility of uridine nucleosides in the treatment of cachexia |
| WO1994026280A1 (fr) * | 1993-05-19 | 1994-11-24 | Korea Green Cross Corporation | Remede contre l'arthrite contenant de l'uridine comme ingredient actif |
| US5567689A (en) * | 1993-08-13 | 1996-10-22 | The Uab Research Foundation | Methods for increasing uridine levels with L-nucleosides |
| US5852000A (en) * | 1993-08-25 | 1998-12-22 | Otsuka Pharmaceutical Factory, Inc. | Cardiac rehabilitation agent |
| WO1996001115A1 (en) * | 1994-07-01 | 1996-01-18 | Pro-Neuron, Inc. | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| US5753625A (en) * | 1995-05-12 | 1998-05-19 | Sangstat Medical Corporation | Treatment for inhibiting the progression of autoimmune disease |
| US5962459A (en) * | 1996-05-28 | 1999-10-05 | Polifarma S.P.A. | Therapeutic active agent for treatment of neuron degenerative diseases |
| US5789391A (en) * | 1996-07-03 | 1998-08-04 | Inspire Pharmaceuticals, Inc. | Method of treating sinusitis with uridine triphosphates and related compounds |
| SE9701219D0 (sv) * | 1997-04-04 | 1997-04-04 | Astra Pharma Prod | New compounds |
| EP1019725A2 (de) * | 1997-07-22 | 2000-07-19 | Novimmune Sa | Verfahren zur diagnose und therapie von autoimmunen krankheiten, wie insulin abhängiges diabetes mellitus mitels retorviraler superantigene |
| US20020006913A1 (en) * | 1997-11-04 | 2002-01-17 | Von Borstel Reid W. | Antimutagenic compositions for treatment and prevention of photodamage to skin |
| US6673606B1 (en) * | 2000-04-12 | 2004-01-06 | The Children's Hospital Of Philadelphia | Therapeutic uses for mesenchymal stromal cells |
-
1999
- 1999-05-05 SE SE9901615A patent/SE521031C2/sv not_active IP Right Cessation
-
2000
- 2000-05-02 WO PCT/SE2000/000827 patent/WO2000067759A1/en not_active Ceased
- 2000-05-02 EP EP07102064A patent/EP1790348A3/de not_active Withdrawn
- 2000-05-02 AU AU52592/00A patent/AU776520B2/en not_active Ceased
- 2000-05-02 AT AT00937418T patent/ATE367164T1/de not_active IP Right Cessation
- 2000-05-02 CA CA002373052A patent/CA2373052A1/en not_active Abandoned
- 2000-05-02 DE DE60035583T patent/DE60035583T2/de not_active Expired - Fee Related
- 2000-05-02 BR BR0010283-0A patent/BR0010283A/pt not_active Application Discontinuation
- 2000-05-02 JP JP2000616785A patent/JP2002544165A/ja active Pending
- 2000-05-02 EP EP00937418A patent/EP1181021B1/de not_active Expired - Lifetime
-
2001
- 2001-11-02 US US09/986,522 patent/US20020061863A1/en not_active Abandoned
-
2004
- 2004-11-22 US US10/994,663 patent/US7687476B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000067759A1 (en) | 2000-11-16 |
| EP1790348A2 (de) | 2007-05-30 |
| DE60035583D1 (de) | 2007-08-30 |
| US20050090467A1 (en) | 2005-04-28 |
| AU776520B2 (en) | 2004-09-16 |
| SE9901615L (sv) | 2000-12-15 |
| EP1181021A1 (de) | 2002-02-27 |
| US20020061863A1 (en) | 2002-05-23 |
| US7687476B2 (en) | 2010-03-30 |
| BR0010283A (pt) | 2003-07-29 |
| SE9901615D0 (sv) | 1999-05-05 |
| DE60035583T2 (de) | 2008-04-17 |
| EP1790348A3 (de) | 2007-06-13 |
| AU5259200A (en) | 2000-11-21 |
| EP1181021B1 (de) | 2007-07-18 |
| CA2373052A1 (en) | 2000-11-16 |
| JP2002544165A (ja) | 2002-12-24 |
| SE521031C2 (sv) | 2003-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200000059T2 (tr) | Piridin türevleri | |
| EP1549767A4 (de) | Modulation der expression von forkhead-box o1a | |
| BR9502707A (pt) | Composto composição farmacêutica e método para o tratamento de uma afecção | |
| BR0107241A (pt) | Compostos, processo de preparação dos compostos, uso dos compostos, composições fungicidas, processo de combate preventivo ou curativo dos fungos fitopatogênicos das culturas e método de tratamento preventivo ou curativo da madeira de construção | |
| WO2005055944A3 (en) | Oligosaccharide compositions and use thereof in the treatment of infection | |
| DE60043868D1 (de) | Abgeschwächte Mikroorganismen für die Behandlung von Infektionen | |
| HK1049115A1 (zh) | 治療過敏性失調的成分和方法 | |
| DE60235545D1 (de) | Verfahren zur behandlung von nagelpilz und anderen mikrobiellen und mykotischen erkrankungen und dafür geeignete zusammensetzungen | |
| TR200103634T2 (tr) | Bitkilerde flavonoidlerin ve fenolik maddelerin miktarını arttırma yöntemi. | |
| ATE335499T1 (de) | Zusammensetzungen zur behandlung von staphylococcus aureus infektionen | |
| ATE429916T1 (de) | Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme | |
| PT1537274E (pt) | Tratamento enzimatico de feltros de prensa | |
| DE60237039D1 (de) | Verfahren zur behandlung von rosacea und telangiectasia | |
| ATE402924T1 (de) | Pyridiniumsalze und deren verwendung | |
| ATE367164T1 (de) | Verwendung von 4-thiouridin oder isomaltitol zur behandlung von entzündungen und/oder hämostasis | |
| DE69931784D1 (de) | Chemotaxis hemmendes protein von staphylococcus aureus (chips) und dessen verwendung | |
| ATE359808T1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
| ATE260097T1 (de) | Hopfensäuren zur hemmung von staphylococcus aureus | |
| ATE206052T1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
| EP1056458A4 (de) | Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen | |
| ATE453386T1 (de) | Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten | |
| DE69906701D1 (de) | Topische verwendung von loperamid zur behandlung mikrobieller infektionen | |
| ATE340182T1 (de) | Sucroseoctasulphat silber saltz | |
| DE69716056D1 (de) | Acylurea-verbindungen zur behandlung von coccidioidomycosis bei warmblütigen tieren | |
| ATE361085T1 (de) | Verwendung einer zusätzlich fermentierten getreideschlempe zur vorbeugung und/oder behandlung erhähter blutzucker-werte |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |